Patents by Inventor Vera VORONINA

Vera VORONINA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210068378
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.
    Type: Application
    Filed: September 24, 2020
    Publication date: March 11, 2021
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Vera Voronina, Cagan Gurer
  • Publication number: 20210051930
    Abstract: The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 25, 2021
    Inventors: Lynn Macdonald, Andrew J. Murphy, John McWhirter, Naxin Tu, Vera Voronina, Cagan Gurer, Karolina Meagher, Sean Stevens
  • Publication number: 20210029978
    Abstract: Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Ig? light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig? light chains, in whole or in part, that are encoded by human Ig? light chain-encoding sequences inserted into an endogenous Ig? light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.
    Type: Application
    Filed: September 24, 2020
    Publication date: February 4, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Chunguang Guo, Faith Harris, Vera Voronina, John McWhirter, Natasha Levenkova, Lynn Macdonald, Naxin Tu, Andrew J. Murphy
  • Patent number: 10869466
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of the human immune system are provided.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: December 22, 2020
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
  • Publication number: 20200375160
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: August 12, 2020
    Publication date: December 3, 2020
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
  • Publication number: 20200375159
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: August 6, 2020
    Publication date: December 3, 2020
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • Patent number: 10820582
    Abstract: Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Ig? light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig? light chains, in whole or in part, that are encoded by human Ig? light chain-encoding sequences inserted into an endogenous Ig? light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: November 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Chunguang Guo, Faith Harris, Vera Voronina, John McWhirter, Natasha Levenkova, Lynn Macdonald, Naxin Tu, Andrew J. Murphy
  • Patent number: 10820581
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: November 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Vera Voronina, Cagan Gurer
  • Patent number: 10779520
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: September 22, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • Publication number: 20200002731
    Abstract: Compositions and methods are provided for creating and promoting biallelic targeted modifications to genomes within cells and for producing non-human animals comprising the modified genomes. Also provided are compositions and methods for modifying a genome within a cell that is heterozygous for an allele to become homozygous for that allele. The methods make use of Cas proteins and two or more guide RNAs that target different locations within the same genomic target locus. Also provided are methods of identifying cells with modified genomes.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Ka-Man Venus Lai, Wojtek Auerbach, Gustavo Droguett, Anthony Gagliardi, David M. Valenzuela, Vera Voronina, Lynn Macdonald, Andrew J. Murphy, George D. Yancopoulos
  • Publication number: 20200002730
    Abstract: Compositions and methods are provided for creating and promoting biallelic targeted modifications to genomes within cells and for producing non-human animals comprising the modified genomes. Also provided are compositions and methods for modifying a genome within a cell that is heterozygous for an allele to become homozygous for that allele. The methods make use of Cas proteins and two or more guide RNAs that target different locations within the same genomic target locus. Also provided are methods of identifying cells with modified genomes.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Ka-Man Venus Lai, Wojtek Auerbach, Gustavo Droguett, Anthony Gagliardi, David M. Valenzuela, Vera Voronina, Lynn Macdonald, Andrew J. Murphy, George D. Yancopoulos
  • Publication number: 20190380316
    Abstract: Non-human animals and methods and compositions for making and using them are provided, which non-human animals have a genome comprising an engineered or recombinant diversity cluster within an immunoglobulin heavy chain variable region, which engineered or recombinant diversity cluster comprises an insertion of one or more DH segments that are each operably linked to a 23-mer recombination signal sequence. Methods for producing antibodies from non-human animals are also provided, which antibodies optionally contain human variable regions and rodent, e.g., constant regions.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 19, 2019
    Inventors: Andrew J. Murphy, Lynn Macdonald, Chunguang Guo, John McWhirter, Vera Voronina
  • Patent number: 10457960
    Abstract: Compositions and methods are provided for creating and promoting biallelic targeted modifications to genomes within cells and for producing non-human animals comprising the modified genomes. Also provided are compositions and methods for modifying a genome within a cell that is heterozygous for an allele to become homozygous for that allele. The methods make use of Cas proteins and two or more guide RNAs that target different locations within the same genomic target locus. Also provided are methods of identifying cells with modified genomes.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: October 29, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Ka-Man Venus Lai, Wojtek Auerbach, Gustavo Droguett, Anthony Gagliardi, David M. Valenzuela, Vera Voronina, Lynn Macdonald, Andrew J. Murphy, George D. Yancopoulos
  • Publication number: 20190290783
    Abstract: Provided herein are methods and compositions related to the in vivo testing of therapeutic agents comprising a human Fc in genetically modified rodents (e.g., the testing of the pharmacokinetic and/or pharmacodynamic properties of such a therapeutic agent in genetically modified rodents). In some embodiments the genetically modified rodents express antibodies comprising a human Fc (e.g., a human IgG1 Fc, a human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (i.e., antibodies having human heavy chains and human light (? or ?) chains). In certain embodiments the genetically modified rodents comprise one or more Fc receptors with a human extracellular domain (e.g., a Neonatal Fc Receptor (FcRn), a ?-2-microglobulin polypeptide (?2M), a Fc ? receptor 1? (Fc?R1?), a Fc ? receptor 1 alpha (Fc?R1a), a Fc gamma receptor 2a (Fc?R2a), a Fc gamma receptor 2b (Fc?R2b), a Fc gamma receptor 3a (Fc?R3a), a Fc gamma receptor 3b (Fc?R3b), a Fc gamma receptor 2c (Fc?R2c)).
    Type: Application
    Filed: March 25, 2019
    Publication date: September 26, 2019
    Inventors: Vera VORONINA, Corey Momont, John McWhirter, Naxin Tu, Lynn MacDonald, Andrew J. Murphy
  • Publication number: 20190239496
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: January 10, 2019
    Publication date: August 8, 2019
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • Publication number: 20190239497
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: January 10, 2019
    Publication date: August 8, 2019
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • Patent number: 10314296
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 11, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Vera Voronina, Cagan Gurer, Andrew J. Murphy, Lynn Macdonald, Yingzi Xue
  • Publication number: 20190133095
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: November 8, 2018
    Publication date: May 9, 2019
    Inventors: Lynn Macdonald, Andrew J. Murphy, Vera Voronina, Cagan Gurer
  • Patent number: 10219493
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the humanized MHC II protein. Also provided are constructs for and methods of making said genetically modified non-human animals. Methods of using the genetically modified non-human animals to study various aspects of the human immune system are provided.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: March 5, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • Patent number: 10154658
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: December 18, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Vera Voronina, Cagan Gurer